---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-000341"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:29:52.399346+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q2 beats; raises FY26 guidance; CEO Clemmer to retire; Med Tech growth +13%

## Summary
- Q2 net sales $79.4M (+8.8% YoY); Med Tech $35.7M (+13.0%); GAAP EPS -$0.15, adj. EPS $0.00.
- Raised FY26 net sales guidance to $312-314M (from $308-313M); Adj. EBITDA raised to $8-10M (from $6-10M).
- CEO Jim Clemmer to retire in FY2027; board initiates search; Q2 generated $4.7M cash, debt-free balance sheet.
- FDA IDE approvals for APEX-Return (AlphaVac blood management) and PAVE (AngioVac right-sided endocarditis) studies.
- Federal Circuit affirmed Bard patent invalidation, eliminating $3M contingent payment obligation from prior settlement.

## SEC filing metadata
- accession: 0001140361-26-000341
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036126000341/0001140361-26-000341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036126000341/ef20062354_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-000341
- JSON: https://secwatch.observer/filing/0001140361-26-000341.json
- Plain text: https://secwatch.observer/filing/0001140361-26-000341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.